Copyright Reports & Markets. All rights reserved.

Global Human Coagulation Factor VIII Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Human Coagulation Factor VIII Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Recombinant Factor VIII
    • 1.3.3 Plasma-derived Factor VIII
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Human Coagulation Factor VIII Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hemophilia A
    • 1.4.3 Spontanous / Trauma
    • 1.4.4 Surgical
    • 1.4.5 Other
  • 1.5 Global Human Coagulation Factor VIII Market Size & Forecast
    • 1.5.1 Global Human Coagulation Factor VIII Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Human Coagulation Factor VIII Sales Quantity (2020-2031)
    • 1.5.3 Global Human Coagulation Factor VIII Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 Takeda
    • 2.1.1 Takeda Details
    • 2.1.2 Takeda Major Business
    • 2.1.3 Takeda Human Coagulation Factor VIII Product and Services
    • 2.1.4 Takeda Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Takeda Recent Developments/Updates
  • 2.2 Bayer
    • 2.2.1 Bayer Details
    • 2.2.2 Bayer Major Business
    • 2.2.3 Bayer Human Coagulation Factor VIII Product and Services
    • 2.2.4 Bayer Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Bayer Recent Developments/Updates
  • 2.3 CSL
    • 2.3.1 CSL Details
    • 2.3.2 CSL Major Business
    • 2.3.3 CSL Human Coagulation Factor VIII Product and Services
    • 2.3.4 CSL Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 CSL Recent Developments/Updates
  • 2.4 Pfizer
    • 2.4.1 Pfizer Details
    • 2.4.2 Pfizer Major Business
    • 2.4.3 Pfizer Human Coagulation Factor VIII Product and Services
    • 2.4.4 Pfizer Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Pfizer Recent Developments/Updates
  • 2.5 Grifols
    • 2.5.1 Grifols Details
    • 2.5.2 Grifols Major Business
    • 2.5.3 Grifols Human Coagulation Factor VIII Product and Services
    • 2.5.4 Grifols Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Grifols Recent Developments/Updates
  • 2.6 Biogen
    • 2.6.1 Biogen Details
    • 2.6.2 Biogen Major Business
    • 2.6.3 Biogen Human Coagulation Factor VIII Product and Services
    • 2.6.4 Biogen Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Biogen Recent Developments/Updates
  • 2.7 Octapharma
    • 2.7.1 Octapharma Details
    • 2.7.2 Octapharma Major Business
    • 2.7.3 Octapharma Human Coagulation Factor VIII Product and Services
    • 2.7.4 Octapharma Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Octapharma Recent Developments/Updates
  • 2.8 NovoNordisk
    • 2.8.1 NovoNordisk Details
    • 2.8.2 NovoNordisk Major Business
    • 2.8.3 NovoNordisk Human Coagulation Factor VIII Product and Services
    • 2.8.4 NovoNordisk Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 NovoNordisk Recent Developments/Updates
  • 2.9 Greencross
    • 2.9.1 Greencross Details
    • 2.9.2 Greencross Major Business
    • 2.9.3 Greencross Human Coagulation Factor VIII Product and Services
    • 2.9.4 Greencross Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Greencross Recent Developments/Updates
  • 2.10 Kedrion
    • 2.10.1 Kedrion Details
    • 2.10.2 Kedrion Major Business
    • 2.10.3 Kedrion Human Coagulation Factor VIII Product and Services
    • 2.10.4 Kedrion Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Kedrion Recent Developments/Updates
  • 2.11 BPL
    • 2.11.1 BPL Details
    • 2.11.2 BPL Major Business
    • 2.11.3 BPL Human Coagulation Factor VIII Product and Services
    • 2.11.4 BPL Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 BPL Recent Developments/Updates
  • 2.12 Hualan Bio
    • 2.12.1 Hualan Bio Details
    • 2.12.2 Hualan Bio Major Business
    • 2.12.3 Hualan Bio Human Coagulation Factor VIII Product and Services
    • 2.12.4 Hualan Bio Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.12.5 Hualan Bio Recent Developments/Updates
  • 2.13 RAAS
    • 2.13.1 RAAS Details
    • 2.13.2 RAAS Major Business
    • 2.13.3 RAAS Human Coagulation Factor VIII Product and Services
    • 2.13.4 RAAS Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.13.5 RAAS Recent Developments/Updates
  • 2.14 SinoCellTech
    • 2.14.1 SinoCellTech Details
    • 2.14.2 SinoCellTech Major Business
    • 2.14.3 SinoCellTech Human Coagulation Factor VIII Product and Services
    • 2.14.4 SinoCellTech Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.14.5 SinoCellTech Recent Developments/Updates
  • 2.15 Taibang Bio
    • 2.15.1 Taibang Bio Details
    • 2.15.2 Taibang Bio Major Business
    • 2.15.3 Taibang Bio Human Coagulation Factor VIII Product and Services
    • 2.15.4 Taibang Bio Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.15.5 Taibang Bio Recent Developments/Updates
  • 2.16 Huarun Boya
    • 2.16.1 Huarun Boya Details
    • 2.16.2 Huarun Boya Major Business
    • 2.16.3 Huarun Boya Human Coagulation Factor VIII Product and Services
    • 2.16.4 Huarun Boya Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.16.5 Huarun Boya Recent Developments/Updates
  • 2.17 Shuanglin Bio
    • 2.17.1 Shuanglin Bio Details
    • 2.17.2 Shuanglin Bio Major Business
    • 2.17.3 Shuanglin Bio Human Coagulation Factor VIII Product and Services
    • 2.17.4 Shuanglin Bio Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.17.5 Shuanglin Bio Recent Developments/Updates
  • 2.18 Yuandashuyang
    • 2.18.1 Yuandashuyang Details
    • 2.18.2 Yuandashuyang Major Business
    • 2.18.3 Yuandashuyang Human Coagulation Factor VIII Product and Services
    • 2.18.4 Yuandashuyang Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.18.5 Yuandashuyang Recent Developments/Updates
  • 2.19 Weiguang Bio
    • 2.19.1 Weiguang Bio Details
    • 2.19.2 Weiguang Bio Major Business
    • 2.19.3 Weiguang Bio Human Coagulation Factor VIII Product and Services
    • 2.19.4 Weiguang Bio Human Coagulation Factor VIII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.19.5 Weiguang Bio Recent Developments/Updates

3 Competitive Environment: Human Coagulation Factor VIII by Manufacturer

  • 3.1 Global Human Coagulation Factor VIII Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Human Coagulation Factor VIII Revenue by Manufacturer (2020-2025)
  • 3.3 Global Human Coagulation Factor VIII Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Human Coagulation Factor VIII by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Human Coagulation Factor VIII Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Human Coagulation Factor VIII Manufacturer Market Share in 2024
  • 3.5 Human Coagulation Factor VIII Market: Overall Company Footprint Analysis
    • 3.5.1 Human Coagulation Factor VIII Market: Region Footprint
    • 3.5.2 Human Coagulation Factor VIII Market: Company Product Type Footprint
    • 3.5.3 Human Coagulation Factor VIII Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Human Coagulation Factor VIII Market Size by Region
    • 4.1.1 Global Human Coagulation Factor VIII Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Human Coagulation Factor VIII Consumption Value by Region (2020-2031)
    • 4.1.3 Global Human Coagulation Factor VIII Average Price by Region (2020-2031)
  • 4.2 North America Human Coagulation Factor VIII Consumption Value (2020-2031)
  • 4.3 Europe Human Coagulation Factor VIII Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Human Coagulation Factor VIII Consumption Value (2020-2031)
  • 4.5 South America Human Coagulation Factor VIII Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Human Coagulation Factor VIII Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Human Coagulation Factor VIII Sales Quantity by Type (2020-2031)
  • 5.2 Global Human Coagulation Factor VIII Consumption Value by Type (2020-2031)
  • 5.3 Global Human Coagulation Factor VIII Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Human Coagulation Factor VIII Sales Quantity by Application (2020-2031)
  • 6.2 Global Human Coagulation Factor VIII Consumption Value by Application (2020-2031)
  • 6.3 Global Human Coagulation Factor VIII Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Human Coagulation Factor VIII Sales Quantity by Type (2020-2031)
  • 7.2 North America Human Coagulation Factor VIII Sales Quantity by Application (2020-2031)
  • 7.3 North America Human Coagulation Factor VIII Market Size by Country
    • 7.3.1 North America Human Coagulation Factor VIII Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Human Coagulation Factor VIII Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Human Coagulation Factor VIII Sales Quantity by Type (2020-2031)
  • 8.2 Europe Human Coagulation Factor VIII Sales Quantity by Application (2020-2031)
  • 8.3 Europe Human Coagulation Factor VIII Market Size by Country
    • 8.3.1 Europe Human Coagulation Factor VIII Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Human Coagulation Factor VIII Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Human Coagulation Factor VIII Market Size by Region
    • 9.3.1 Asia-Pacific Human Coagulation Factor VIII Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Human Coagulation Factor VIII Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Human Coagulation Factor VIII Sales Quantity by Type (2020-2031)
  • 10.2 South America Human Coagulation Factor VIII Sales Quantity by Application (2020-2031)
  • 10.3 South America Human Coagulation Factor VIII Market Size by Country
    • 10.3.1 South America Human Coagulation Factor VIII Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Human Coagulation Factor VIII Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Human Coagulation Factor VIII Market Size by Country
    • 11.3.1 Middle East & Africa Human Coagulation Factor VIII Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Human Coagulation Factor VIII Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Human Coagulation Factor VIII Market Drivers
  • 12.2 Human Coagulation Factor VIII Market Restraints
  • 12.3 Human Coagulation Factor VIII Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Human Coagulation Factor VIII and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Human Coagulation Factor VIII
  • 13.3 Human Coagulation Factor VIII Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Human Coagulation Factor VIII Typical Distributors
  • 14.3 Human Coagulation Factor VIII Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Human Coagulation Factor VIII market size was valued at US$ 11880 million in 2024 and is forecast to a readjusted size of USD 17970 million by 2031 with a CAGR of 6.2% during review period.
    Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
    Market Drivers:
    The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.
    Market Challenges:
    Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.
    This report is a detailed and comprehensive analysis for global Human Coagulation Factor VIII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Human Coagulation Factor VIII market size and forecasts, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
    Global Human Coagulation Factor VIII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
    Global Human Coagulation Factor VIII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Bottles), and average selling prices (USD/Bottle), 2020-2031
    Global Human Coagulation Factor VIII market shares of main players, shipments in revenue ($ Million), sales quantity (K Bottles), and ASP (USD/Bottle), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Human Coagulation Factor VIII
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Human Coagulation Factor VIII market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Human Coagulation Factor VIII market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Recombinant Factor VIII
    Plasma-derived Factor VIII
    Market segment by Application
    Hemophilia A
    Spontanous / Trauma
    Surgical
    Other
    Major players covered
    Takeda
    Bayer
    CSL
    Pfizer
    Grifols
    Biogen
    Octapharma
    NovoNordisk
    Greencross
    Kedrion
    BPL
    Hualan Bio
    RAAS
    SinoCellTech
    Taibang Bio
    Huarun Boya
    Shuanglin Bio
    Yuandashuyang
    Weiguang Bio
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Human Coagulation Factor VIII product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Human Coagulation Factor VIII, with price, sales quantity, revenue, and global market share of Human Coagulation Factor VIII from 2020 to 2025.
    Chapter 3, the Human Coagulation Factor VIII competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Human Coagulation Factor VIII breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Coagulation Factor VIII market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Human Coagulation Factor VIII.
    Chapter 14 and 15, to describe Human Coagulation Factor VIII sales channel, distributors, customers, research findings and conclusion.

    Buy now